Renalytix AI (GB:RENX) has released an update.
Renalytix AI, a leader in AI-enabled in-vitro diagnostics for kidney health, has announced its total issued share capital stands at 154,368,191 Ordinary Shares, with each share granting one vote in company meetings. Shareholders can use this number as a reference for disclosing changes in their stakes as per regulatory requirements. The company’s kidneyintelX.dkd test has gained distinction as the first FDA-authorized prognostic test for early-stage chronic kidney disease risk assessment in patients with type 2 diabetes.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
